Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

V disease and is administered by intramuscular injection. The safety and efficacy of Synagis were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of prematurity (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease. The first dose of Synagis should be administered prior to commencement of the RSV season, which usually starts in the fall and runs through the spring. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.

Very rare cases (<1 per 100,000 patients) of anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. Cases of anaphylaxis were reported following re-exposure to Synagis and rare severe hypersensitivity reactions occurred on initial exposure or re-exposure. If a severe hypersensitivity reaction occurs, therapy with Synagis should be permanently discontinued. If milder hypersensitivity reaction occurs, caution should be used on re-administration of Synagis.

In clinical trials, the most common adverse events occurring at least one percent more frequently in Synagis-treated patients than controls were upper respiratory infection, otitis media, fever and rhinitis. Cyanosis and arrhythmia were seen in children with CHD.

The pivotal trial for Synagis was called the IMpact trial and comprised a total of 1,502 children who were randomized (500 placebo, 1,002 Synagis) in a double-blind, placebo-controlled protocol where 1,486 children completed the study's follow-up.

In the IMpact trial, monthly prophylaxis with Synagis via intramuscular injections was associated with a 55-percent reduction in hospitalization as a result of RSV (p=<0.001). Reductions were observed in both children with bronchopulmonary dysplasia (38 percent reduction) and premature children without BPD (78 percent reduction). Approximately 50 percent of the
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Reportbuyer.com has added a ... Densitometers Market 2014-2018 https://www.reportbuyer.com/product/2225723/Global-Bone-Densitometers-Market-2014-2018.html ... scan is a special type of X-ray test used ... is used primarily to detect osteopenia or osteoporosis, diseases ... risk of fractures is high. The purpose of bone ...
(Date:7/28/2014)... , July 28, 2014 Reportlinker.com announces ... in its catalogue: Portugal Pharmaceuticals ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes ... View: Faster-than-expected economic growth last quarter has led ... slightly upwards. As forecast previously, BMI expects ...
(Date:7/28/2014)... NORWALK, Conn. , July 28, 2014  UBM ... , a leading online community for medical imaging professionals, ... value in value-based payment models . The ... in identifying how the radiologist,s reimbursement is determined ... article features insight from leaders in the field, who ...
Breaking Medicine Technology:Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Diagnostic Imaging Delves into Measuring the Radiologist's Value 2
... Calif., July 15, 2011 Amgen (NASDAQ: ... States (U.S.) District Court in Pennsylvania has entered ... Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA prohibiting ... G-CSF (granulocyte colony-stimulating factor) and methods for its ...
... EDISON, N.J., July 15, 2011 Crestor ... designed to lower "bad cholesterol". Both drugs are classified ... inhibiting HMG-CoA reductase. This group of drugs has had ... to Crestor and Zocor, touted as a "super statin" ...
Cached Medicine Technology:Amgen Resolves G-CSF Patent Litigation With Teva 2Crestor and Zocor Drugs Linked to Muscle Degeneration, Rhabdomyolysis 2
(Date:7/29/2014)... California (PRWEB) July 29, 2014 ... of the peer-reviewed journal Lipids in Health and ... value—of Nordic Naturals triglyceride-form best-selling Ultimate Omega®/ProOmega®. Consistently ... according to SPINS scan data, the product was ... to other omega-3 products in the marketplace. The ...
(Date:7/29/2014)... “Our years of experience with ... to insulate their homes properly simply due to ... heat transfer and conduction,” Clean Crawls says in ... released an article explaining exactly how heat ... bills. , To contact Clean Crawls for their ...
(Date:7/29/2014)... Bethesda, Maryland (PRWEB) July 29, 2014 ... has been named a 2014 ASAE Power of ... Flu-Focused," a public awareness campaign to encourage everyone age ... annually. , ASAE recognized NFID for its power ... drive awareness and action among consumers and professionals about ...
(Date:7/29/2014)... 2014 “Approximately 18% of our population ... common chronic illnesses,” Western Washington Medical Group says in ... for those suffering from allergies to seek medical attention. ... care each year in the United States,” they continue. ... of life for themselves, rather than seeking the appropriate ...
(Date:7/29/2014)... 29, 2014 The Eleventh Annual Business ... concluded with the $10,000 prize being presented to Ambika ... ) , The 11th Annual Summit was held on ... who can bring innovative products and services for the ... to have had such excellent array of young companies ...
Breaking Medicine News(10 mins):Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 2Health News:Study Shows Nordic Naturals® Triglyceride-Form Ultimate Omega®/ProOmega® More Effective Than Krill Oil, Salmon Oil, and Ethyl Ester Fish Oil 3Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2Health News:National Foundation for Infectious Diseases Receives Top ASAE Honors for Keeping the Nation Flu-Focused 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3Health News:Silicon Valley Boomer Venture Summit Names Bikanta Competition Winner 2
... DOMA Vector and DOMA Technologies to provide Record Conversion Services to more ... the Pacific. DOMA will convert millions of veteran treatment records from ... service to our veterans while reducing cost. , ... Virginia Beach, Va. ...
... DIEGO, May 7 Brandes Investment Partners, L.P. ("Brandes") ... submitted to Mitsui Sumitomo Insurance Group Holdings, Inc. (the ... on the Tokyo Stock Exchange, a proposal for a ... at the Company,s upcoming annual meeting of shareholders. ...
... weathering recession at national ALFA conferencePHILADELPHIA , ... executives today expressed confidence in the state of ... the conclusion of a national conference here.The executives ... far better than other businesses because it had ...
... Mobilization Campaign Urges Congress to Make Health Reform Work ... Hospital at Stanford is joining the National ... to launch a grassroots mobilization campaign asking Congress and ... for children. "Our hospital is extraordinarily proud ...
... WASHINGTON, May 7 The following is ... of the American Health Care Association (AHCA), Dave Kyllo, ... (NCAL) and Alan G. Rosenbloom, President of the Alliance ... the Obama Administration,s commitment to creating new jobs and ...
... May 7 Acting in response to concerns about ... Hotels and Resorts (TM), a privately held operator ... North America and Europe, today announced a three-phase program ... and provide reassurance about the safety of its facilities.(logo: ...
Cached Medicine News:Health News:Veterans Administration Awards Small Business' $13 Million Contract to Digitize Veterans Health Records 2Health News:Brandes Proposes 40 yen Per Share Dividend for Mitsui Sumitomo Insurance Group Holdings, Inc. Annual Meeting 2Health News:Brandes Proposes 40 yen Per Share Dividend for Mitsui Sumitomo Insurance Group Holdings, Inc. Annual Meeting 3Health News:Brandes Proposes 40 yen Per Share Dividend for Mitsui Sumitomo Insurance Group Holdings, Inc. Annual Meeting 4Health News:Brandes Proposes 40 yen Per Share Dividend for Mitsui Sumitomo Insurance Group Holdings, Inc. Annual Meeting 5Health News:Brandes Proposes 40 yen Per Share Dividend for Mitsui Sumitomo Insurance Group Holdings, Inc. Annual Meeting 6Health News:Senior Living Executives Optimistic About Future 2Health News:Lucile Packard Children's Hospital at Stanford to Raise Its Voice for Kids in Health Care Reform Debate 2Health News:Lucile Packard Children's Hospital at Stanford to Raise Its Voice for Kids in Health Care Reform Debate 3Health News:Joint Statement from AHCA, NCAL, and the Alliance on the Obama Administration's FY 2010 Budget 2Health News:Dolce Hotels and Resorts Initiates Program to Mitigate H1N1 Flu Risk 2
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
The Plasmacup SC satisfies two important requirements: high primary stability and a low friction bearing surface....
... The integration of Trabecular Metal ... proven implant design results in a ... not only meets surgeon demands for ... provides a wide variety of shell ...
The cementless BiHAPro cup combines proven concepts with the latest innovations in cementless THR....
Medicine Products: